Macquarie Group LTD Protagonist Therapeutics, Inc Transaction History

Macquarie Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $2,413 - $3,594	-307 Closed	0 $3,000
Q2 2021 Aug 13, 2021	SELL	$25.57 - $44.88 $36,616 - $64,268	-1,432 Reduced 82.35%	307 $14,000
Q1 2021 May 14, 2021	BUY	$19.02 - $31.15 $33,075 - $54,169	1,739 New	1,739 $45,000
Q1 2019 May 15, 2019	SELL	$6.5 - $13.77 $14,833 - $31,423	-2,282 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$6.3 - $10.44 $26,107 - $43,263	-4,144 Reduced 64.49%	2,282 $15,000
Q3 2018 Nov 15, 2018	SELL	$6.82 - $11.26 $45,694 - $75,442	-6,700 Reduced 51.04%	6,426 $66,000
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $46,123 - $70,070	7,700 Added 141.91%	13,126 $88,000
Q1 2018 May 11, 2018	BUY	$8.46 - $23.08 $45,903 - $125,232	5,426 New	5,426 $47,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.